1 who underwent allo-SCT after 450 cGy TBI in addition to CY 20 mg/kg. At the time of the report, 10 patients were alive, fully engrafted and without evidence of disease.
Shortly after publication and 7 years after successful SCT, one of the reported patients (patient UPN 990, now 19 years of age) presented for routine check-up. Her laboratory work-up revealed pancytopenia and subsequent bone marrow examination showed 40% cellularity with dysplastic changes in granulocyte and erythroid precursors and 30% myeloid blasts. Diagnosis of AML was made based on morphologic and immunophenotypic analysis according to the FAB criteria; flow cytometric immunophenotyping revealed positivity of CD33, CD34, CD13, CD117 and CD56. At the same time, chimerism (STR) studies on peripheral blood demonstrated the presence of 100% donor cells in both the lymphoid and myeloid lineages. However, sex-mismatch FISH studies on the bone marrow specimen without preceding cell separation showed 65% donor cells and 35% recipient cells.
The co-existence of neoplastic female host cells and normal male donor cells was confirmed by the patient's bone marrow karyotype. Cytogenetic analysis of 20 GTGbanded metaphase spreads from bone marrow aspirate short-term cultures revealed two unrelated clones and the karyotype was 47,XX,À7, t(17;18)(p13;q11.2), add(21)(q22) Â 2, þ add(21)(q22), þ 22 [10] /46,XY [10] . The complex chromosomal abnormalities of the neoplastic clone are depicted in Figure 1 and include monosomy 7, the balanced t(17;18), three rearranged chromosomes 21 with a break within band 21q22 and the extra chromosome 22. The presence of monosomy 7 was confirmed by FISH with a chromosome 7 enumeration probe. In addition, the balanced nature of the t(17;18) was proven by FISH using whole chromosome painting probes for chromosomes 17 and 18.
FISH studies using a locus-specific probe of the AML1 gene at chromosome band 21q22 detected AML1 high-level amplification. Additional copies of AML1 were located on each of the three rearranged chromosomes 21 as shown in a representative metaphase spread in Figure 2 .
Three of the chromosomal abnormalities seen in the posttransplant AML were already present in the pre-SCT bone marrow showing 46,XX,À7, þ der(18)t(17;18)(p13;q11.2), add(21)(q22) [20] . This diagnostic karyotype was established 7 years earlier and bone marrow morphology was consistent with MDS. The current findings indicate acquisition of additional chromosomal changes in the posttransplant AML specimen, and hence clonal evolution during MDS/AML progression. The cytogenetic data also indicate that the MDS clone persisted in spite of conditioning with CY and TBI.
AML1 is one of the genes most frequently deregulated in leukemia through different mechanisms, including translocation, mutation and amplification. Although uncommon, AML1 gene amplification is a recurrent chromosomal abnormality in ALL, mainly in childhood ALL, and has been described in over 20 cases. More rarely, AML1 amplification has been reported in myeloid malignancies including MDS and AML. As in our case, all 11 previously published MDS/AML bone marrow karyotypes with AML1 amplification were cytogenetically characterized by derivatives of chromosome 21. [2] [3] [4] [5] Interestingly, also all abnormal ALL karyotypes with AML1 amplification had intra-chromosomally rearranged chromosomes 21. In conclusion, MDS/AML with 21q22 rearrangement and concomitant AML1 amplification seems to evolve as a distinct cytogenetic subgroup in MDS/AML and ALL. Clinical data on AML1 amplification positive ALL show poor outcome for these patients.
Children with FA have a markedly increased risk of myeloid malignancies. MDS is a poor outcome indicator in FA patients and monosomy 7 in bone marrow cells is well correlated with both an increased risk of developing AML and poor prognosis. 6 Thus, we and others have advocated more intense conditioning regimens using TBI for FA patients presenting with such findings. 1, 7 Despite the fact that second transplants may be successful in those FA patients who fail their first SCT, 8 the graft failure associated with recurrence of MDS/ leukemia or clonal chromosomal changes may be more difficult to manage and consequently the outcome may be less satisfactory and only few such cases have been reported in the literature. Tan et al. 9 described a patient with MDS who relapsed almost 5 months after the first SCT (conditioning was with CY/fludarabine/ATG). He was retransplanted 10 months after the first SCT using CY and TBI, but despite full engraftment and morphologic and cytogenetic remission, the patient subsequently relapsed and died 48 months after the first SCT. Also, Bonfim et al. 10 reported four patients in their series who had MDS or pre-SCT chromosomal changes failing their first SCT.
One of the patients was reported to have complex cytogenetic abnormalities before the second SCT. Despite successful engraftment of the second SCT, she died of viral infection on day 75 after the second SCT. Our patient declined any further therapy.
Arguably, graft failure with or without relapse of MDS in FA patients after allo-SCT is not unusual. [8] [9] [10] However, the relapse of MDS/AML in our patient so belatedly after using a TBI-containing regimen underscores the need of vigorous conditioning for these patients and raises an important question about the role of TBI in the conditioning of such patients and whether intensifying the conditioning by using higher doses of TBI or non-radiation intensive chemotherapy may be justified in this particular group of FA patients to ensure the complete eradication of the abnormal pre-leukemic clone. Moreover, the paradox of having residual host cells in the marrow of our patient in face of 100% donor cell engraftment in the peripheral blood at the time of relapse emphasizes the need for close long-term follow-up of these patients and suggests that probably post-SCT bone marrow examinations should be considered yearly on these patients for an extended period of time to monitor chimerism and to detect the 
